News

Pfizer's sickle cell drug fails late-stage trial

Pfizer's experimental drug to treat sickle cell anemia failed to meet the main goal in a late stage trial, the drugmaker said ...

Pfizer: This Is What Bulls Waited For

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...
mlive on MSN4d

‘Potential exposure’ at Portage Pfizer plant sends people to hospital, MIOSHA investigating

Several workers reported symptoms of being exposed to a substance and some were taken to the hospital. The state is ...

Pfizer's sickle-cell treatment efforts falter as drug fails study

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...

Pfizer fails in late-stage trial for sickle cell disease therapy

Pfizer (PFE) stock slips as a Phase 3 trial failure for its sickle cell disease therapy inclacumab marks the latest setback ...

Pfizer's combination therapy improves survival in bladder cancer trial

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Pfizer Raises Profit Outlook Despite Uncertainty Over Tariffs, Drug Prices

Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.